Company intelligence / Profile preview

Highlight Therapeutics

Paterna, Comunidad Valenciana / Valencian Community, Spainhighlighttherapeutics.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Lead candidate BO‑112 has shown the ability to initiate a strong immune response against tumors by making them more visible to the immune system. It has demonstrated potential both as monotherapy and in combination with checkpoint inhibitors, especially for patients resistant to current therapies. Clinical trials are ongoing or recently completed in basal cell carcinoma and other solid tumors. No active trials currently listed on ClinicalTrials.gov as of latest check.

Therapeutic areas: Oncology
Modalities: RNA-based therapies (specifically intra-lesional RNA-based therapy)
Industry: Biotech

Drug pipeline

2 assets

nanoplexed poly I:C

1 more asset in the full pipeline.

Request access →

Partnerships

Merck & Co.UCLA

Beyond the preview

Go deeper on Highlight Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Highlight Therapeutics.

Explore the full profile